BMC Psychiatry最新文献

{"title":"Quantification and time course of subjective psychotropic and somatic effects of tetrahydrocannabinol - a prospective, single-blind, placebo-controlled exploratory trial in healthy volunteers.","authors":"Maren Kleine-Brueggeney, Markus Huber, Lorenz Theiler, Fritz Priemer, Robert Greif","doi":"10.1186/s12888-024-06338-2","DOIUrl":"https://doi.org/10.1186/s12888-024-06338-2","url":null,"abstract":"<p><strong>Background: </strong>Cannabis is increasingly used and debates about the legalisation of the recreational use of cannabis are ongoing. In this prospective, placebo-controlled study in healthy volunteers not regularly consuming cannabis, subjective psychotropic and somatic effects after a single dose of intravenous THC were assessed and quantified over 48 h.</p><p><strong>Methods: </strong>Twenty-five healthy volunteers received a single IV bolus of THC and 6 received normal saline. Psychotropic and somatic effects of THC were assessed by two questionnaires that were completed at up to 14 timepoints from shortly before drug administration to 48 h later.</p><p><strong>Results: </strong>Demographic data did not differ between groups. Differences between THC and placebo for all assessed effects, except for euphoria, irritation and headache, were clearly discernible. Subdimensions related to positive mood were less and those related to negative mood were more pronounced in the THC group. Peak plasma concentrations were observed at 1 to 5 min after THC administration while peak effects occurred between 45 and 60 min. Differences between THC and placebo were pronounced and seen for up to 90 to 120 min for most effects, except for \"sleepiness\" and \"deactivation\", where the effect of THC was discernible for up to 5 h. At 24 and 48 h, there were no statistically significant difference between THC and placebo group.</p><p><strong>Conclusions: </strong>THC triggers a large range of psychotropic and somatic effects with peak effects at 45 to 60 min after IV administration of THC, much later than plasma peak levels. Most effects are short-lasting with a duration of up to 2 h, but some effects like sleepiness and deactivation can be longer-lasting and persist for 5 h or longer in cannabis-naïve or cannabis-abstinent individuals. Since effects of THC demonstrate a time course that differs from the time course of plasma concentrations it might be important to base the judgment of a possible impairment related to THC consumption on clinical or behavioral tests in addition to THC plasma levels.</p><p><strong>Trial registration: </strong>www.isrctn.com ; registration number ISRCTN53019164.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"24 1","pages":"902"},"PeriodicalIF":3.4,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking cessation and harm reduction: a systematic overview of ongoing, randomized controlled trials.","authors":"Mara Derissen, Sebastian Scheliga, Benjamin Clemens, Delia Leiding, Knut Kröger, Hinrich Böhner, Ute Habel","doi":"10.1186/s12888-024-06342-6","DOIUrl":"https://doi.org/10.1186/s12888-024-06342-6","url":null,"abstract":"<p><strong>Background: </strong>Smoking remains one of the major public health threats, necessitating substantial scientific and societal interest in further developing and implementing systematic, smoking cessation trials. This review examines ongoing randomized controlled trials (RCTs) on smoking cessation and harm reduction, focusing on adherence to German S3 guidelines for tobacco dependence and identifying areas needing further research and neglected aspects in the implementation of treatment guidelines for tobacco dependence.</p><p><strong>Methods: </strong>A systematic search was conducted on the International Clinical Trials Registry Platform, comprising multiple trial registries worldwide, to identify ongoing RCTs focusing on smoking cessation and harm reduction. Utilizing the PICOS-scheme, we focused on trials targeting the general population, with biochemical verification, psychological counseling, telemedicine, and nicotine replacement therapy /smoking cessation medication or electronic nicotine delivery systems. Exclusion criteria included trials marked as \"completed,\" \"terminated,\" \"unknown,\" or \"withdrawn.\".</p><p><strong>Results: </strong>The review identified 30 ongoing RCTs, with a majority located in North America. A significant number of trials focus on socioeconomically disadvantaged or uninsured populations, while few address cancer survivors or individuals with smoking-related diseases. Nicotine replacement therapy or smoking cessation medication is consistently used across trials, but with varying regimens. Psychotherapeutic interventions are employed in 22 trials, with motivational interviewing being the most common method. Only four trials utilize electronic nicotine delivery systems as a harm reduction strategy. The lack of standardized reporting in trial registries was a significant barrier to synthesizing and categorizing information. Geographic representation is predominantly in North America, suggesting a need for more diverse trial locations.</p><p><strong>Conclusions: </strong>There is a critical need for more RCTs involving electronic nicotine delivery systems and tailored psychotherapeutic interventions. Expanding trial locations beyond North America and standardizing trial reporting could enhance the global applicability of smoking cessation strategies. Future research should focus on the long-term risks and benefits of electronic nicotine delivery systems, particularly in high-risk populations. This approach will aid in developing more effective and culturally relevant smoking cessation guidelines.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"24 1","pages":"897"},"PeriodicalIF":3.4,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of health anxiety with quality of life among medical students in Egypt: Myth or Menace?","authors":"Mohamed Terra, Mohamed Baklola, Lena Said Mansour, Nour Edin Darwish, Mennatallah Elsayed Badr, Amira A Alghazali, Jinan Ali A Almumtin, Fayrouz Mohamed Fahmy, Abdel-Hady El-Gilany","doi":"10.1186/s12888-024-06313-x","DOIUrl":"10.1186/s12888-024-06313-x","url":null,"abstract":"<p><strong>Background: </strong>Health anxiety (HA) is a prevalent concern among medical students, potentially impacting their academic performance and Quality of Life (QoL). This study aims to assess the prevalence of HA and its predictors among medical students in Egypt and its correlation with the Quality of Life.</p><p><strong>Methods: </strong>A descriptive cross-sectional study was conducted during the 2022-2023 academic year across ten Egyptian medical schools. A total of 1,173 students participated by completing an online questionnaire, which included the Short Health Anxiety Inventory (SHAI) and the 12-Item Short Form Survey (SF-12). Data were analyzed using SPSS 25. Chi-square tests, crude odds ratios (COR) with 95% confidence intervals, and Pearson's correlation coefficients were utilized for statistical analysis. A p-value ≤ 0.05 was considered statistically significant.</p><p><strong>Results: </strong>This study found that 15.7% of participants experienced clinically significant HA. Female students (17.5%) and students dissatisfied with their academic performance (18%) exhibited a significantly higher prevalence of HA. A significant negative correlation was observed between HA and QoL (r = -0.393, p ≤ 0.05), with students experiencing HA reporting lower QoL scores. Key predictors of HA included female gender (OR = 1.41, 95% CI: 1.01-1.96) and lack of academic satisfaction (OR = 1.43, 95% CI: 1.04-1.96).</p><p><strong>Conclusion: </strong>Health anxiety (HA) is a notable issue among Egyptian medical students, particularly affecting females and those dissatisfied with their academic performance and is closely linked to reduced quality of life. Effective interventions could enhance the overall educational experience, helping students improve their well-being and manage HA's impacts on their personal and academic lives.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"24 1","pages":"895"},"PeriodicalIF":3.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facing depression: evaluating the efficacy of the EmpkinS-EKSpression reappraisal training augmented with facial expressions - protocol of a randomized controlled trial.","authors":"Marie Keinert, Lena Schindler-Gmelch, Lydia Helene Rupp, Misha Sadeghi, Klara Capito, Malin Hager, Farnaz Rahimi, Robert Richer, Bernhard Egger, Bjoern M Eskofier, Matthias Berking","doi":"10.1186/s12888-024-06361-3","DOIUrl":"10.1186/s12888-024-06361-3","url":null,"abstract":"<p><strong>Background: </strong>Dysfunctional depressogenic cognitions are considered a key factor in the etiology and maintenance of depression. In cognitive behavioral therapy (CBT), the current gold-standard psychotherapeutic treatment for depression, cognitive restructuring techniques are employed to address dysfunctional cognitions. However, high drop-out and non-response rates suggest a need to boost the efficacy of CBT for depression. This might be achieved by enhancing the role of emotional and kinesthetic (i.e., body movement perception) features of interventions. Therefore, we aim to evaluate the efficacy of a cognitive restructuring task augmented with the performance of anti-depressive facial expressions in individuals with and without depression. Further, we aim to investigate to what extent kinesthetic markers are intrinsically associated with and, hence, allow for the detection of, depression.</p><p><strong>Methods: </strong>In a four-arm, parallel, single-blind, randomized controlled trial (RCT), we will randomize 128 individuals with depression and 128 matched controls without depression to one of four study conditions: (1) a cognitive reappraisal training (CR); (2) CR enhanced with instructions to display anti-depressive facial expressions (CR + AFE); (3) facial muscle training focusing on anti-depressive facial expressions (AFE); and (4) a sham control condition. One week after diagnostic assessment, a single intervention of 90-120-minute duration will be administered, with a subsequent follow-up two weeks later. Depressed mood will serve as primary outcome. Secondary outcomes will include current positive mood, symptoms of depression, current suicidality, dysfunctional attitudes, automatic thoughts, emotional state, kinesthesia (i.e., facial expression, facial muscle activity, body posture), psychophysiological measures (e.g., heart rate (variability), respiration rate (variability), verbal acoustics), as well as feasibility measures (i.e., treatment integrity, compliance, usability, acceptability). Outcomes will be analyzed with multiple methods, such as hierarchical and conventional linear models and machine learning.</p><p><strong>Discussion: </strong>If shown to be feasible and effective, the inclusion of kinesthesia into both psychotherapeutic diagnostics and interventions may be a pivotal step towards the more prompt, efficient, and targeted treatment of individuals with depression.</p><p><strong>Trial registration: </strong>The study was preregistered in the Open Science Framework on August 12, 2022 ( https://osf.io/mswfg/ ) and retrospectively registered in the German Clinical Trials Register on November 25, 2024.</p><p><strong>Clinical trial number: </strong>DRKS00035577.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"24 1","pages":"896"},"PeriodicalIF":3.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered brain regional homogeneity, depressive symptoms, and cognitive impairments in medication-free female patients with current depressive episodes in bipolar disorder and major depressive disorder.","authors":"Sulin Ni, Ting Peng, Shuzhan Gao, Chenxi Ling, Fan Wu, Jing Jiang, Jing Sun, Chaoyong Xiao, Xijia Xu","doi":"10.1186/s12888-024-06352-4","DOIUrl":"10.1186/s12888-024-06352-4","url":null,"abstract":"<p><strong>Background: </strong>Although symptoms of depressive episodes in patients with bipolar depressive episodes (BDE) and major depressive disorder (MDD) are similar, the treatment strategies for these disorders are completely different, suggesting that BDE and MDD have different neurobiological backgrounds. In this study, we examined the relationship between brain function and clinical symptoms, particularly cognitive function, in female individuals with bipolar disorder and MDD experiencing depressive episodes.</p><p><strong>Methods: </strong>Regional homogeneity (ReHo) was analyzed in 51 medication-free female patients with BDE, 63 medication-free female patients with MDD, and 45 female healthy controls (HCs). Depressive symptom severity was assessed using the 24-item Hamilton Depression Rating Scale (HAMD-24), and multidimensional cognitive function was evaluated using the MATRICS Consensus Cognition Battery. Partial correlation analysis was used to explore the links between the brain regions and clinical characteristics. A support vector machine (SVM) was used to assess the classification accuracy.</p><p><strong>Results: </strong>Compared with HCs, patients with BDE and MDD had decreased ReHo in the left lobule VI of the cerebellum and increased ReHo in the left precuneus. Patients with BDE also had reduced ReHo in the left lobules IV-V of the cerebellum and increased ReHo in the right putamen, unlike patients with MDD who had no significant differences in these regions. Patients with BDE exhibited more severe cognitive deficits in processing speed, attention, word learning, and overall cognitive function than those with MDD. In patients with BDE, a significant negative correlation was found between the right putamen and HAMD-24 scores. However, no significant association was observed between abnormal ReHo levels and cognitive function. The SVM effectively differentiated between patients with BDE, MDD, and HCs.</p><p><strong>Conclusion: </strong>Cognitive impairment was more severe in female patients with BDE than in those with MDD. Changes in the ReHo values of the right putamen and left lobules IV-V may serve as unique neuroimaging markers for BDE. Alterations in the ReHo values of the left precuneus and left lobule VI could serve as common pathophysiological mechanisms for BDE and MDD in women and indicate depressive states.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"24 1","pages":"892"},"PeriodicalIF":3.4,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142790980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in loneliness, social isolation, and their impact on psychiatric symptoms and cognitive functioning in schizophrenia.","authors":"Jinghui Chi, Nannan Liu, Tian Tian, Qiaona Jiang, Chenghao Lu, Yanzhe Li, Xiaofei Zhang, Yanyan Ma, Lili Wang, Shen Li","doi":"10.1186/s12888-024-06333-7","DOIUrl":"10.1186/s12888-024-06333-7","url":null,"abstract":"<p><strong>Background: </strong>Social isolation and loneliness, objective and subjective features of dysfunctional social relationships, are more prevalent in patients with schizophrenia (SCZ) than in the general population. This study aimed to explore sex differences in loneliness and social isolation among Chinese chronic SCZ patients, and to investigate their relationships with psychiatric symptoms and cognitive functioning.</p><p><strong>Methods: </strong>A total of 323 SCZ patients, comprising 136 males and 187 females, were recruited. Psychopathology, cognitive functioning, loneliness, social isolation were assessed using the Positive and Negative Syndrome Scale (PANSS), the Repeated Battery for Assessment of Neuropsychological Status (RBANS), the UCLA (University of California, Los Angeles) Loneliness Scale (Version 3) and the Social Isolation Index (ISI). Multiple linear regression models were conducted to test the independent, relative, and synergistic efects of loneliness and social isolation on psychiatric symptoms and cognitive performance for male and female patients separately.</p><p><strong>Results: </strong>Male patients exhibited higher UCLA loneliness scale scores and social isolation scores compared to female patients (p_s < 0.05). In male patients, both loneliness and social isolation significantly predicted PANSS total scores (p_s< 0.01), negative subscale scores (p_s < 0.05) and general psychopathology subscale scores (p_s < 0.05). For female patients, loneliness (not social isolation) significantly predicted immediate memory (p < 0.001), language (p = 0.013), delayed memory (p = 0.017), and RBANS total scores (p = 0.002). Further examination of loneliness components in female patients revealed that personal feelings of isolation were negatively associated with language (r = -0.21, p = 0.001) and a negative correlation exists between lack of collective connectedness and delayed memory (r = -0.19, p = 0.048).</p><p><strong>Conclusion: </strong>Loneliness and social isolation are more pronounced in male SCZ patients than in female patients. Both loneliness and social isolation are positively related to psychiatric symptoms in male patients, while loneliness is negatively associated with cognitive functioning in female patients.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"24 1","pages":"894"},"PeriodicalIF":3.4,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142790968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between dyslipidemia and depression: a cross-sectional analysis of NHANES data from 2007 to 2018.","authors":"Xuemin Zhong, Jinxuan Ming, Changqing Li","doi":"10.1186/s12888-024-06359-x","DOIUrl":"10.1186/s12888-024-06359-x","url":null,"abstract":"<p><strong>Background: </strong>The relationship between depression and dyslipidemia remains controversial, with inconsistent findings across studies. This study aimed to investigate the association between blood lipid levels and depression using data from the National Health and Nutrition Examination Survey (NHANES) spanning from 2007 to 2018.</p><p><strong>Methods: </strong>This cross-sectional study included 12,819 adult participants from NHANES. Depression was assessed using a nine-item depression screening instrument. Serum lipid levels, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG), were measured using Roche modular P and Roche Cobas 6000 chemistry analyzers. Survey-weighted multiple logistic regression was used to assess the relationships between serum lipid levels and depression.</p><p><strong>Results: </strong>We observed a statistically significant negative association between HDL levels and depression (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.58-0.90). After adjustments for covariates, HDL-C, TG, and the triglyceride glucose (TyG) index showed significant associations with depression (ORs: 0.66, 1.08, and 1.01, respectively). A linear correlation was observed between HDL-C levels and depression (P < 0.01), while TG levels and the TyG index exhibited nonlinear associations (p < 0.01 and p < 0.05, respectively). No significant positive associations were observed between increased TC or LDL-C levels and the risk of depression.</p><p><strong>Conclusions: </strong>High HDL-C levels were negatively associated with depression, while TG levels and the TyG index were positively associated with depression. Clinical attention should be given to the detection of lipid levels in patients with depression.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"24 1","pages":"893"},"PeriodicalIF":3.4,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142790987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in psychiatric disorder incidence patterns during the COVID-19 pandemic in Korea: a study using the nationwide universal health insurance data.","authors":"Changwoo Han, Juho Choi, Hoyeon Jang, Hwa-Young Lee, Tarik Benmarhnia, Juhwan Oh","doi":"10.1186/s12888-024-06325-7","DOIUrl":"10.1186/s12888-024-06325-7","url":null,"abstract":"<p><strong>Background: </strong>Few studies have evaluated the incidence of various psychiatric disorders during the coronavirus disease (COVID-19) pandemic using hospital visit data for the entire population of a nation. We used Korea's universal compulsory health insurance data to conduct a descriptive analysis to evaluate changes in psychiatric disorder incidence during the COVID-19 pandemic.</p><p><strong>Methods: </strong>Hospital visit data related to psychiatric disorders were retrieved from the National Health Insurance Database. First-ever diagnosis for specific psychiatric disorders for each Korean was identified (from January 2015 to February 2023) and monthly age-standardized incidence rates were calculated. An interrupted time-series analysis was used to estimate counterfactual disease incidence rates and observed and counterfactual rates were compared using difference-in-difference framework.</p><p><strong>Results: </strong>Compared to pre-pandemic period, there was a decrease in the incidence [percentage changes in monthly rate (95% confidence intervals)] of organic mental disorders [-14.6% (-18.4, -10.9)] and psychoactive substance related disorders [-12.9% (-17.5, -8.3)] during the pandemic. However, anxiety disorders [8.8% (3.1, 14.6)], behavioral syndromes associated with physiological disturbances [8.1% (4.2, 11.9)], mental retardation [8.6% (3.0, 14.2)], psychological developmental disorders [19.6% (11.5, 27.7)], childhood- and adolescent-onset behavioral and emotional disorders [45.1% (28.4, 61.8)], and unspecified mental diseases [51.8% (39.8, 63.8)] increased.</p><p><strong>Conclusions: </strong>Psychological disease incidence patterns changed substantially during the pandemic in South Korea. Various pandemic-related stressors, such as disrupted lifestyles and hospital accessibility, may have influenced these changes. The causes and public health consequences of these changes require further evaluation.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"24 1","pages":"889"},"PeriodicalIF":3.4,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142783982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"REWRITALIZE your recovery: a study protocol for a randomised controlled trial (RCT) examining the effectiveness of the new recovery-oriented creative writing group intervention REWRITALIZE for people with severe mental illness.","authors":"Susanne Henningsson, Jon Toke Brestisson, Siv-Therese Bogevik Bjørkedal, Birgit Bundesen, Keld Stehr Nielsen, Bea Ebersbach, Carsten Hjorthøj, Lene Falgaard Eplov","doi":"10.1186/s12888-024-06254-5","DOIUrl":"10.1186/s12888-024-06254-5","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Health institutions advocate for psychosocial and recovery-oriented interventions alongside pharmacological treatment for severe mental illness. Participatory arts interventions appear promising in promoting personal recovery by fostering connectedness, hope, renegotiation of identity, meaning-making, and empowerment. Despite encouraging findings, however, the evidence base remains thin. Further, results from cognitive literature studies suggest possible impact on parameters of clinical recovery, but this has not been studied in clinical contexts. We developed REWRITALIZE, a structured, recovery-oriented, fifteen-session creative writing group intervention led by a professional author alongside a mental health professional. Participants engage with literary forms, write on them, share their texts, and partake in reflective discussions within a supportive, non-stigmatising environment, designed to promote self-expression, playful experimentation, agency, recognition, participatory meaning-making, renegotiation of identity and social engagement. The aim of this project is to evaluate REWRITALIZE for persons with severe mental illness through a randomised controlled trial (RCT) focusing on personal recovery outcomes. Additionally, an embedded pilot RCT will explore additional outcomes i.e., clinical recovery for a subgroup with schizophrenia spectrum disorders.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The RCT is an investigator-initiated, randomised, two-arm, assessor-blinded, multi-center, waiting-list superiority trial involving 300 participants (age &gt; 18) from six psychiatric centers in regions Capital and Zealand in Denmark, randomised to receive either the creative writing intervention combined with standard treatment or standard treatment alone. Assessments will be conducted before and after the intervention and at six months post intervention. The primary outcome is personal recovery at the end of intervention measured with the questionnaire of the process of recovery. Secondary outcomes include other measures of personal recovery, self-efficacy, mentalising, and quality of life. The pilot RCT, integrated within the RCT, will focus on 70 of the participants aged 18-35 with schizophrenia spectrum disorders, evaluating exploratory measures related to perspective-taking, social cognition, cognitive function, psychosocial functioning, and symptom pressure.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;This is the first RCT for creative writing groups. It assesses whether REWRITALIZE, as adjunct to standard mental healthcare, is more effective for personal recovery than standard care. If successful, it would provide evidence for the efficacy of REWRITALIZE, potentially enabling its implementation across mental health centers in Denmark.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Trial registration: &lt;/strong&gt;Privacy (data protection agency): p-2023-14655. Danish National Center for Ethics: 2313949.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Clinicaltrials: &lt;/strong&gt;gov: NCT06251908. Registrati","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"24 1","pages":"891"},"PeriodicalIF":3.4,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between C-reactive protein-triglyceride glucose index and depressive symptoms in American adults: results from the NHANES 2005 to 2010.","authors":"Chaojuan Huang, Hongtao You, Yuyang Zhang, Zhiwei Li, Mingxu Li, Xingliang Feng, Naiyuan Shao","doi":"10.1186/s12888-024-06336-4","DOIUrl":"10.1186/s12888-024-06336-4","url":null,"abstract":"<p><strong>Background: </strong>The novel serum C-reactive protein-triglyceride glucose index (CTI) has been identified as an ideal parameter that integrates inflammation and insulin resistance, which are potential mechanisms underlying depressive symptoms. Our research aimed to investigate the association between CTI and depressive symptoms.</p><p><strong>Methods: </strong>Our cross-sectional investigation utilized data from the National Health and Nutrition Examination Survey conducted between 2005 and 2010. The integrated CTI was calculated as 0.412 × Ln (C-reactive protein) (mg/dL) + Ln [triglyceride (mg/dL) × fasting glucose (mg/dL)/2]. The severity of depressive symptoms was evaluated through the continuous Patient Health Questionnaire-9 (PHQ-9) scores, and the categorical definition of depressive symptoms (PHQ-9 score ≥ 10) reflected moderate to severe symptoms. Survey-weighted linear and logistic regression models were conducted to establish the correlation between CTI and PHQ-9 scores, and between CTI and depressive symptoms. Moreover, subgroup analyses, interaction tests, and smoothed curve fitting were performed to scrutinize the steadiness of the results.</p><p><strong>Results: </strong>A total of 5,954 participants were enrolled in our study, including 477 with depressive symptoms and 5,477 without. The results revealed a significant positive relationship between CTI and PHQ-9 scores (β: 0.40, 95% CI: 0.25,0.55, p < 0.001) and depressive symptoms (OR: 1.30, 95% CI: 1.06,1.61, p = 0.02). Additionally, individuals in the fourth quartile of CTI exhibited a higher likelihood of depressive symptoms than those in the first quartile (PHQ-9 score: β: 0.83, 95% CI: 0.39,1.26, p < 0.001; depressive symptoms: OR: 2.00, 95% CI:1.19,3.36, p = 0.01). Smooth curve fitting and subgroup analyses consistently demonstrated the positive relationship.</p><p><strong>Conclusions: </strong>Elevated CTI was correlated with a higher risk of depressive symptoms, underscoring CTI as a potential clinical indicator for identifying and stratifying depressive symptoms.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"24 1","pages":"890"},"PeriodicalIF":3.4,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142783849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}